What are the potential risks and benefits of administering low molecular weight heparin for thromboprophylaxis in cancer patients during hospitalization?

Low molecular weight heparin is effective for thromboprophylaxis in hospitalized cancer patients, significantly reducing VTE incidence. It has a favorable risk profile, though monitoring for bleeding and HIT is essential.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24322893
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

What are the potential risks and benefits of administering low molecular weight heparin for thromboprophylaxis in cancer patients during hospitalization?

Tripdatabase
5 links
Zenodo (CERN European Organization for Nuclear Research)
Venous Thromboembolism Diagnosis and Management
article

What are the potential risks and benefits of administering low molecular weight heparin for thromboprophylaxis in cancer patients during hospitalization?

Tripdatabase
article en

Abstract

Low molecular weight heparin is effective for thromboprophylaxis in hospitalized cancer patients, significantly reducing VTE incidence. It has a favorable risk profile, though monitoring for bleeding and HIT is essential.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon